Back to top
more

Glaukos (GKOS)

(Delayed Data from NYSE)

$88.06 USD

88.06
1,764,464

+0.56 (0.64%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $88.11 +0.05 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 6.98% and 4.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

What to Expect From These 3 MedTech Stocks This Earnings Season?

by Indrajit Bandyopadhyay

Here is a sneak peek into how three MedTech stocks, GKOS, ITGR and AMN, are expected to fare in their quarterly results, slated to be released tomorrow.

Zacks Equity Research

What Analyst Projections for Key Metrics Reveal About Glaukos (GKOS) Q4 Earnings

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Glaukos (GKOS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.

Zacks Equity Research

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

by Zacks Equity Research

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Zacks Equity Research

Should iShares S&P Small-Cap 600 Growth ETF (IJT) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IJT

Zacks Equity Research

Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPSM

Zacks Equity Research

Mesa Labs (MLAB) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of 8.98% and 4.91%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VIOG

Zacks Equity Research

Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SLYG

Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Intuitive Surgical (ISRG) delivered earnings and revenue surprises of 24.86% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Zacks Equity Research

NeuroPace (NPCE) Soars 9.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

GKOS Stock Gains Following Positive Study Data on iDose Platform

by Zacks Equity Research

Glaukos' iDose TR achieves lasting IOP reduction and safety, transforming glaucoma treatment. The company is progressing well with its next-generation iDose TREX.

Zacks Equity Research

Here's Why You Should Add Glaukos Stock to Your Portfolio Now

by Zacks Equity Research

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Zacks Equity Research

Glaukos Reaches 52-Week High: What's Driving the Stock's Rally?

by Zacks Equity Research

Investors are optimistic about GKOS' strength in its product portfolio amid robust demand and expansion in new markets.

Zacks Equity Research

Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA

by Zacks Equity Research

GKOS announces New Drug Application submission for its Epioxa to the FDA.

Zacks Equity Research

The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen

by Zacks Equity Research

Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.

Zacks Equity Research

Here's Why You Should Add Glaukos Stock to Your Portfolio Now

by Zacks Equity Research

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Indrajit Bandyopadhyay headshot

5 Medical Device Stocks That Survived the 2024 Market Volatility

by Indrajit Bandyopadhyay

Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.

Zacks Equity Research

Should iShares S&P Small-Cap 600 Growth ETF (IJT) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IJT

Zacks Equity Research

Strong Segmental Sales to Drive Cooper Companies Q4 Earnings?

by Zacks Equity Research

COO's fiscal fourth-quarter results are likely to reflect segmental strength.

Zacks Equity Research

Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SLYG

Zacks Equity Research

Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally?

by Zacks Equity Research

GKOS stock gains from strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.

Zacks Equity Research

Should JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for BBSC

Zacks Equity Research

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH